The Michael J. Fox Foundation (MJFF) has prioritized alpha-synuclein imaging as the approach most likely imaging to have an impact on therapeutic development.
To that end, the foundation has issued a request for applications (RFA) for investigator-initiated studies designed to accelerate development of a selective alpha-synuclein PET tracer for use in clinical studies. The foundation encourages multidisciplinary teams to apply and id particularly interested in collaborations between academic and industry groups that have access to diverse compound libraries.
Projects can include compound screening, tissue binding studies, lead identification and optimization, in vivo testing in appropriate models, and first-in-human testing of candidate tracers. Funding priority will be given to teams that show the greatest promise for delivering a selective tracer for human testing at the end of the funding period.
The total amount available through the program is $10 million. A total of $8.5 million is available for the first two years of the program, with the possibility of an additional $1.5 million for the project that shows the most promising results during the initial funding period. (Grant amounts include direct and indirect costs.)
Click here for more information
Contact Us: Office: (302) 588-1342info@philanthropydelaware.org
Address:100 W. 10th Street, Suite 500Wilmington, DE 19801
Copyright Philanthropy Delaware, Inc. 2017Philanthropy Delaware, Inc. is a 501(c)3 nonprofit organization
